NMRA
NASDAQNeumora Therapeutics Inc.
Price$1.61-0.03 (-2.13%)
01:30 PM07:45 PM
News · 26 weeks38+50%
2025-12-142026-06-07
Mix1890d
- SEC Filings8(44%)
- Insider5(28%)
- Other3(17%)
- Earnings2(11%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Burow Kristina4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by Director Fust Matthew K4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by Director Piacquad David4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by Director Halawa Alaa4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by Director Ho Maykin4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- SECSEC Form 8-K filed by Neumora Therapeutics Inc.8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare ConferenceWATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 1:35 p.m. ET. A live webcast of the fireside chat will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived fo
- SECSEC Form 10-Q filed by Neumora Therapeutics Inc.10-Q - Neumora Therapeutics, Inc. (0001885522) (Filer)
- SECNeumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateKOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer's disease agitation and NMRA-898 in schizophrenia with clinical data expected for each program in the second half of 2026 Strong financial position with $147.1 million in cash and cash equivalents expected to support operations into the third quarter of 2027 WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved
- SECSEC Form DEFA14A filed by Neumora Therapeutics Inc.DEFA14A - Neumora Therapeutics, Inc. (0001885522) (Filer)
- SECSEC Form DEF 14A filed by Neumora Therapeutics Inc.DEF 14A - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare ConferenceWATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 10:15 a.m. ET. A live webcast of the fireside chat will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived fo
- SECSEC Form S-8 filed by Neumora Therapeutics Inc.S-8 - Neumora Therapeutics, Inc. (0001885522) (Filer)
- SECSEC Form 10-K filed by Neumora Therapeutics Inc.10-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- SECNeumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateNew data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study Strong financial position with $182.5 million in cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 Company to host conference call today at 8:00 a.m. ET WATERTOWN, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinica
- PRNeumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 30, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of th
- INSIDEROfficer Aurora Daljit Singh sold $21,917 worth of shares (6,165 units at $3.56), decreasing direct ownership by 7% to 82,770 units (SEC Form 4)4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERPresident Pinto Joshua sold $21,093 worth of shares (5,967 units at $3.54), decreasing direct ownership by 9% to 57,783 units (SEC Form 4)4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDEROfficer Berns Paul L sold $34,459 worth of shares (9,819 units at $3.51), decreasing direct ownership by 0.13% to 7,395,185 units (SEC Form 4)4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDEROfficer Milligan Michael Lee sold $5,119 worth of shares (1,436 units at $3.56), decreasing direct ownership by 6% to 21,034 units (SEC Form 4)4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
NMRA FAQ
6 questionsWhere does NMRA stock trade?
Neumora Therapeutics Inc. (NMRA) is listed on NASDAQ.What sector and industry is NMRA in?
Neumora Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Neumora Therapeutics Inc. go public?
Neumora Therapeutics Inc. (NMRA) completed its IPO in 2023.What are analysts saying about NMRA?
Neumora Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-02-17.What companies are similar to NMRA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare NMRA side-by-side with any of them on Quantisnow.How can I track NMRA on Quantisnow?
Quantisnow aggregates Neumora Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NMRA to receive live email and push alerts on every new disclosure.